

Craig J Currie

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5341324/publications.pdf>

Version: 2024-02-01

67
papers

3,279
citations

257101

24
h-index

143772

57
g-index

69
all docs

69
docs citations

69
times ranked

4586
citing authors

#	ARTICLE	IF	CITATIONS
1	Comorbid diseases and conditions in people with HIV in the UK. <i>Current Medical Research and Opinion</i> , 2022, 38, 277-285.	0.9	4
2	The absolute risk of incident type 2 diabetes following exposure to systemic corticosteroids in selected steroid-related and phenotypic groups. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 2222-2231.	2.2	3
3	The financial burden of treating patients presenting with acute and chronic cough. <i>Current Medical Research and Opinion</i> , 2021, 37, 2175-2184.	0.9	7
4	Cough presentation in primary care and the identification of chronic cough: a need for diagnostic clarity?. <i>Current Medical Research and Opinion</i> , 2020, 36, 139-150.	0.9	14
5	Scientific independence and objectivity: many questions linger about treatment of type 2 diabetes, such as scientific study design, optimal glucose control and the safety of injecting exogenous insulin. <i>Postgraduate Medicine</i> , 2020, 132, 667-675.	0.9	0
6	Retinal thickness fluctuations in patients receiving fluocinolone acetonide implant for diabetic macular edema. <i>Current Medical Research and Opinion</i> , 2020, 36, 959-965.	0.9	5
7	Major adverse cardiovascular events in people with chronic kidney disease in relation to disease severity and diabetes status. <i>PLoS ONE</i> , 2019, 14, e0221044.	1.1	24
8	Evaluation of the healthcare resource use and the related financial costs of managing peanut allergy in the United Kingdom. <i>Expert Review of Clinical Immunology</i> , 2019, 15, 889-896.	1.3	8
9	The Model of Mortality with Incident Cirrhosis (MoMIC) and the model of Long-term Outlook of Mortality in Cirrhosis (LOMIC). <i>PLoS ONE</i> , 2019, 14, e0223253.	1.1	1
10	Evaluation of the epidemiology of peanut allergy in the United Kingdom. <i>Expert Review of Clinical Immunology</i> , 2019, 15, 1333-1339.	1.3	12
11	Comparison of data characterizing the clinical effectiveness of the fluocinolone intravitreal implant (ILUVIEN) in patients with diabetic macular edema from the real world, non-interventional ICE-UK study and the FAME randomized controlled trials. <i>Current Medical Research and Opinion</i> , 2019, 35, 1165-1176.	0.9	8
12	Glucose Control and Weight Change Associated with Treatment with Exenatide Compared with Basal Insulin: A Retrospective Study. <i>Diabetes Therapy</i> , 2018, 9, 269-283.	1.2	6
13	Impact of differing glucose-lowering regimens on the pattern of association between glucose control and survival. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 821-830.	2.2	9
14	A genetic programming approach to development of clinical prediction models: A case study in symptomatic cardiovascular disease. <i>PLoS ONE</i> , 2018, 13, e0202685.	1.1	7
15	Hospital admissions for severe infections in people with chronic kidney disease in relation to renal disease severity and diabetes status. <i>Endocrinology, Diabetes and Metabolism</i> , 2018, 1, e00029.	1.0	2
16	Evaluation of the cost-effectiveness of rifaximin for the management of patients with hepatic encephalopathy in the United Kingdom. <i>Current Medical Research and Opinion</i> , 2018, 34, 2001-2008.	0.9	7
17	Impact of treatment with pioglitazone on stroke outcomes: A real-world database analysis. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 2140-2147.	2.2	18
18	Risk of cardiovascular events, arrhythmia and all-cause mortality associated with clarithromycin versus alternative antibiotics prescribed for respiratory tract infections: a retrospective cohort study. <i>BMJ Open</i> , 2017, 7, e013398.	0.8	22

#	ARTICLE	IF	CITATIONS
19	Healthcare resource utilization and related financial costs associated with glucose lowering with either exenatide or basal insulin: <scp>A</scp> retrospective cohort study. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 1097-1105.	2.2	2
20	Evaluation of the clinical effectiveness in routine practice of fluocinolone acetonide 190µg intravitreal implant in people with diabetic macular edema. <i>Current Medical Research and Opinion</i> , 2017, 33, 5-17.	0.9	27
21	Evaluation of the clinical effectiveness of fluocinolone acetonide 190µg intravitreal implant in diabetic macular edema: a comparison between study and fellow eyes. <i>Current Medical Research and Opinion</i> , 2017, 33, 19-31.	0.9	14
22	Patterns of retinal thickness prior to and following treatment with fluocinolone acetonide 190µg intravitreal implant for diabetic macular edema. <i>Current Medical Research and Opinion</i> , 2017, 33, 33-43.	0.9	14
23	Health-economic evaluation of fluocinolone acetonide 190µg implant in people with diabetic macular edema. <i>Current Medical Research and Opinion</i> , 2017, 33, 45-52.	0.9	8
24	Non-Response to Antibiotic Treatment in Adolescents for Four Common Infections in UK Primary Care 1991-2012: A Retrospective, Longitudinal Study. <i>Antibiotics</i> , 2016, 5, 25.	1.5	8
25	The impact on hospital resource utilisation of treatment of hepatic encephalopathy with rifaximin. <i>Liver International</i> , 2016, 36, 1295-1303.	1.9	46
26	Comparative estimated effectiveness of antibiotic classes as initial and secondary treatments of respiratory tract infections: longitudinal analysis of routine data from UK primary care 1991-2012. <i>Current Medical Research and Opinion</i> , 2016, 32, 1023-1032.	0.9	5
27	Natural History of Patients Taking Rifaximin for Recurrent Hepatic Encephalopathy and Risk of Future Overt Episodes and Mortality: A Post-hoc Analysis of Clinical Trials Data. <i>Clinical Therapeutics</i> , 2016, 38, 1081-1089.e4.	1.1	13
28	Association between Insulin Monotherapy versus Insulin plus Metformin and the Risk of All-Cause Mortality and Other Serious Outcomes: A Retrospective Cohort Study. <i>PLoS ONE</i> , 2016, 11, e0153594.	1.1	24
29	Cost of dose escalation in people with rheumatoid arthritis treated with tumour necrosis factor inhibitors across Europe. <i>Clinical and Experimental Rheumatology</i> , 2016, 34, 679-84.	0.4	0
30	Treatment of rheumatoid arthritis with etanercept with reference to disease-modifying anti-rheumatic drugs: long-term safety and survival using prospective, observational data. <i>Rheumatology</i> , 2014, 53, 186-194.	0.9	56
31	Antibiotic treatment failure in four common infections in UK primary care 1991-2012: longitudinal analysis. <i>BMJ</i> , The, 2014, 349, g5493-g5493.	3.0	97
32	Estimation of health-related utility (EQ-5D index) in subjects with seasonal allergic rhinoconjunctivitis to evaluate health gain associated with sublingual grass allergen immunotherapy. <i>Health and Quality of Life Outcomes</i> , 2014, 12, 99.	1.0	14
33	External Validation of the UKPDS Risk Engine in Incident Type 2 Diabetes: A Need for New Type 2 Diabetes-Specific Risk Equations. <i>Diabetes Care</i> , 2014, 37, 537-545.	4.3	42
34	The effect of withdrawal of rosiglitazone on treatment pathways, diabetes control and patient outcomes: A retrospective cohort study. <i>Journal of Diabetes and Its Complications</i> , 2014, 28, 360-364.	1.2	6
35	Mortality after cancer among patients with diabetes mellitus: effect of diabetes duration and treatment: (questionable) classification of diabetic patients based on combination of specific glucose-lowering drugs. <i>Diabetologia</i> , 2014, 57, 2001-2002.	2.9	1
36	Do We Still Need Pioglitazone for the Treatment of Type 2 Diabetes? A risk-benefit critique in 2013. <i>Diabetes Care</i> , 2013, 36, S155-S161.	4.3	86

#	ARTICLE	IF	CITATIONS
37	The prevalence and incidence, resource use and financial costs of treating people with attention deficit/hyperactivity disorder (ADHD) in the United Kingdom (1998 to 2010). <i>Child and Adolescent Psychiatry and Mental Health</i> , 2013, 7, 34.	1.2	60
38	The impact of treatment non-compliance on mortality in people with type 1 diabetes. <i>Journal of Diabetes and Its Complications</i> , 2013, 27, 219-223.	1.2	30
39	Mortality and Other Important Diabetes-Related Outcomes With Insulin vs Other Antihyperglycemic Therapies in Type 2 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 668-677.	1.8	167
40	The Impact of Treatment Noncompliance on Mortality in People With Type 2 Diabetes. <i>Diabetes Care</i> , 2012, 35, 1279-1284.	4.3	194
41	Mortality After Incident Cancer in People With and Without Type 2 Diabetes. <i>Diabetes Care</i> , 2012, 35, 299-304.	4.3	381
42	Do the benefits of analog insulins justify their costs?. <i>Diabetes Management</i> , 2012, 2, 173-175.	0.5	6
43	What Next after Metformin? A Retrospective Evaluation of the Outcome of Second-Line, Glucose-Lowering Therapies in People with Type 2 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, 4605-4612.	1.8	79
44	Endogenous hyperinsulinaemia and exogenous insulin: A common theme between atherosclerosis, increased cancer risk and other morbidities. <i>Atherosclerosis</i> , 2012, 222, 26-28.	0.4	16
45	The relationship between self-reported severe pain and measures of socio-economic disadvantage. <i>European Journal of Pain</i> , 2011, 15, 1107-1111.	1.4	21
46	Clinical Effectiveness of Biphasic Insulin Aspart 30:70 Versus Biphasic Human Insulin 30 in UK General Clinical Practice: A Retrospective Database Study. <i>Clinical Therapeutics</i> , 2011, 33, 27-35.	1.1	5
47	Evaluation of the incremental cost to the National Health Service of prescribing analogue insulin. <i>BMJ Open</i> , 2011, 1, e000258-e000258.	0.8	50
48	Survival as a function of HbA1c in people with type 2 diabetes: a retrospective cohort study. <i>Lancet</i> , The, 2010, 375, 481-489.	6.3	770
49	An overview and commentary on retrospective, continuous glucose monitoring for the optimisation of care for people with diabetes. <i>Current Medical Research and Opinion</i> , 2009, 25, 2389-2400.	0.9	11
50	Descriptive epidemiology of hospitalisation for psoriasis. <i>Current Medical Research and Opinion</i> , 2008, 24, 3487-3491.	0.9	7
51	Evaluation of the cost-effectiveness of insulin glargine versus NPH insulin for the treatment of type 1 diabetes in the UK. <i>Current Medical Research and Opinion</i> , 2007, 23, S7-S19.	0.9	26
52	Comment and Reply on:Relative efficacy/effectiveness and relative costs of treatment with insulin glargine and insulin detemir. <i>Current Medical Research and Opinion</i> , 2007, 23, 1761-1764.	0.9	1
53	The outcome of care in people with type 1 and type 2 diabetes following switching to treatment with either insulin glargine or insulin detemir in routine general practice in the UK: a retrospective database analysis. <i>Current Medical Research and Opinion</i> , 2007, 23, S33-S39.	0.9	29
54	Evaluation of the cost-effectiveness of insulin glargine versus NPH insulin for the treatment of type 2 diabetes in the UK. <i>Current Medical Research and Opinion</i> , 2007, 23, S21-S31.	0.9	27

#	ARTICLE	IF	CITATIONS
55	The prescription cost of managing people with type 1 and type 2 diabetes following initiation of treatment with either insulin glargine or insulin detemir in routine general practice in the UK: a retrospective database analysis. <i>Current Medical Research and Opinion</i> , 2007, 23, S41-S48.	0.9	28
56	Multivariate models of health-related utility and the fear of hypoglycaemia in people with diabetes. <i>Current Medical Research and Opinion</i> , 2006, 22, 1523-1534.	0.9	236
57	The impact of the overactive bladder on health-related utility and quality of life. <i>BJU International</i> , 2006, 97, 1267-1272.	1.3	54
58	Evaluation of the costs and outcomes from changes in risk factors in type 2 diabetes using the Cardiff stochastic simulation cost-utility model (DiabForecaster). <i>Current Medical Research and Opinion</i> , 2006, 22, 121-129.	0.9	69
59	The Routine Collation of Health Outcomes Data from Hospital Treated Subjects in the Health Outcomes Data Repository (HODaR): Descriptive Analysis from the First 20,000 Subjects. <i>Value in Health</i> , 2005, 8, 581-590.	0.1	77
60	Anticoagulation in patients with non-valvular atrial fibrillation: an evaluation of stability and early factors that predict longer-term stability on warfarin in a large UK population. <i>Current Medical Research and Opinion</i> , 2005, 21, 1905-1913.	0.9	21
61	Impact of hypoglycaemia on quality of life and productivity in type 1 and type 2 diabetes. <i>Current Medical Research and Opinion</i> , 2005, 21, 1477-1483.	0.9	201
62	The financial costs of hospital care for people with diabetes who have single and multiple macrovascular complications. <i>Diabetes Research and Clinical Practice</i> , 2005, 67, 144-151.	1.1	20
63	The Demand for Hospital Services for Patients with Epilepsy. <i>Epilepsia</i> , 1998, 39, 537-544.	2.6	14
64	The demand and financial cost of hospital care for diabetes mellitus and its related complications. , 1998, 15, 449-451.		5
65	Hospital Utilization as a Function of Social Deprivation: Diabetes vs Non-Diabetes. , 1997, 14, 589-594.		10
66	Epidemiology and Costs of Acute Hospital Care for Cerebrovascular Disease in Diabetic and Nondiabetic Populations. <i>Stroke</i> , 1997, 28, 1142-1146.	1.0	42
67	Costs of Insulin-dependent Diabetes Mellitus. <i>Diabetic Medicine</i> , 1996, 13, 684-684.	1.2	2